Resolution of Gastroparesis Symptoms With the Removal of a Dipeptidyl Peptidase-4 Inhibitor

被引：0
|
作者：
Nuvvula, Sri [1 ]
Rau, Prashanth [2 ]
Belkin, Dimitri [2 ]
Houghton, Jean Marie [1 ]
机构：
[1] Univ Massachusetts, Med Sch, Worcester, MA USA
[2] Univ Massachusetts, Med Ctr, Worcester, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S3125
引用
收藏
页码：S1289 / S1289
页数：1
相关论文
共 50 条
  • [21] Population Pharmacokinetic Analysis of Dutogliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor
    Marier, Jean-Francois
    Mouksassi, Mohamad-Samer
    Gosselin, Nathalie H.
    Li, Jianke
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 297 - 304
  • [22] Localized bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor treatment
    Oya, Kazumasa
    Fujii, Masanao
    Taguchi, Shijima
    Nishie, Wataru
    Izumi, Kentaro
    Shimizu, Hiroshi
    EUROPEAN JOURNAL OF DERMATOLOGY, 2018, 28 (02) : 250 - 251
  • [23] Evaluation of dipeptidyl peptidase-4 inhibitor-associated gastrointestinal symptoms using the prescription claims database
    Funabashi, Ayana
    Ito, Hitoshi
    Maeda, Mamoru
    Hasegawa, Yoshitaka
    Tsukioka, Ryota
    Onda, Mitsuko
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [24] Linagliptin: A Novel Methylxanthin Based Approved Dipeptidyl Peptidase-4 Inhibitor
    Agrawal, Ritesh
    Jain, Pratima
    Dikshit, S. N.
    CURRENT DRUG TARGETS, 2012, 13 (07) : 970 - 983
  • [25] The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice
    Al Suleimani, Yousuf M.
    Abdelrahman, Aly M.
    Karaca, Turan
    Manoj, Priyadarsini
    Ashique, Mohammed
    Nemmar, Abderrahim
    Ali, Badreldin H.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 97 : 1102 - 1108
  • [26] Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
    Bergman, Arthur J.
    Cote, Josee
    Yi, Bingming
    Marbury, Thomas
    Swan, Suzanne K.
    Smith, William
    Gottesdiener, Keith
    Wagner, John
    Herman, Gary A.
    DIABETES CARE, 2007, 30 (07) : 1862 - 1864
  • [27] Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin
    Graefe-Mody, U.
    Friedrich, C.
    Port, A.
    Ring, A.
    Retlich, S.
    Heise, T.
    Halabi, A.
    Woerle, H. -J.
    DIABETES OBESITY & METABOLISM, 2011, 13 (10): : 939 - 946
  • [28] Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes
    Stein, Stephanie A.
    Lamos, Elizabeth M.
    Davis, Stephen N.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (04) : 599 - 608
  • [29] The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
    Blech, Stefan
    Ludwig-Schwellinger, Eva
    Graefe-Mody, Eva Ulrike
    Withopf, Barbara
    Wagner, Klaus
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (04) : 667 - 678
  • [30] IMPACT OF DIPEPTIDYL PEPTIDASE-4 INHIBITOR USE ON THE RISK OF RHEMATOID ARTHRITIS
    Kathe, N. J.
    Shah, A. B.
    Said, Q.
    Painter, J. T.
    VALUE IN HEALTH, 2016, 19 (03) : A225 - A225
12345